Rasonque is a drug owned by Revolution Medicines Inc. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Rasonque's patents will be open to challenges from 26 August, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 24, 2042. Details of Rasonque's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12280113 | Ras Inhibitors |
Jan, 2042
(15 years from now) | Active |
| US12403196 | Ras Inhibitors |
Sep, 2041
(14 years from now) | Active |
FDA has granted several exclusivities to Rasonque. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Rasonque, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Rasonque.
Exclusivity Information
Rasonque holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Rasonque's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Rasonque is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Rasonque's family patents as well as insights into
ongoing legal events
on those patents.
Rasonque's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rasonque:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Revolution Medicines, Inc. | NA | RECRUITING
(Sep 1, 2026) | PHASE1, PHASE2 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | NA | RECRUITING
(Aug 1, 2026) | PHASE3 |
Generic Launch
Generic Release Date:
Rasonque's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 24, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rasonque Generics:
There are no approved generic versions for Rasonque as of now.
About Rasonque
Rasonque is a drug owned by Revolution Medicines Inc. Rasonque uses Daraxonrasib as an active ingredient. Rasonque was launched by Revolution Medicines in 2026.
Approval Date:
Rasonque was approved by FDA for market use on 26 August, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Rasonque is 26 August, 2026, its NCE-1 date is estimated to be 26 August, 2030.
Active Ingredient:
Rasonque uses Daraxonrasib as the active ingredient. Check out other Drugs and Companies using Daraxonrasib ingredient
Dosage:
Rasonque is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | TABLET | Prescription | ORAL |
| 150MG | TABLET | Prescription | ORAL |